Skip to main content
Premium Trial:

Request an Annual Quote

Ontario Funds High Impact Clinical Trials with $12.7M

NEW YORK (GenomeWeb News) – The Ontario Institute for Cancer Research has been awarded C$12.6 million (US$12.7 million) from the provincial government to fund a clinical trials program that will use genomics and personalized medicine in a translational science effort, OICR said Monday.

The funding will be used to support two trials that are part of the High Impact Clinical Trials (HICT) Program over a four-year period.

One of these HICT efforts is the Genomic Cohort Study for Ontario Clinical Trials, which is a collaboration with Princess Margaret Hospital. In this study, researchers will develop standard operating procedures to help safely and effectively integrate genomics technologies with standard clinical practice and to improve patient care. The expectation is that genetic information could be used to help determine how to best match patients to the most optimal treatments to maximize the anti-tumor efficacy and to reduce side-effects.

The other clinical trial is the Rare Tumor Clinical Trials Initiative, a partnership between OICR, Pfizer Canada, and the NCIC Clinical Trials Group at Queens University. This multidisciplinary and multi-center trial will engage genomics researchers and pathologists to develop new ways to study rare tumors.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.